Inhibition of urease by miscellaneous ions and compounds. Implications for the therapy of infection-induced urolithiasis.
One hundred forty-eight drugs and other organic and inorganic substances were screened for their ability to inhibit the enzyme urease in an in  vitro system modeled on infected urine. The reported urease-inhibiting properties of ascorbic acid, tetracyclines, and sulfanilamide were not confirmed. At least 50 per cent inhibition was observed in the presence of kanamvcin, hydroxguanidine, benzoquinone, 1,2-naphthaquinone-4-sulfonate, chloramine-T, N-bromoacetamide, copper, mercury, and fluoride. It is, however, unlikely that therapeutically effective concentrations can be attained in urine without giving dosages likely to result in toxic effects. Hydroxyurea, at the dose level used in cytotoxic therapy, may be expected to produce effective inhibition of bacterial urease in the urinary tract, providing renal function is unimpaired and providing urinary volume does not exceed 1 liter per 24 hr. Acetohydroxamic acid is potentially the most useful drug for the treatment of infection-induced urinary stone disease available at present.
D001424:Bacterial Infections / Q000150:complications; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D006918:Hydroxyurea / Q000494:pharmacology; D066298:In Vitro Techniques; D007477:Ions; D007612:Kanamycin / Q000494:pharmacology; D013424:Sulfanilamides / Q000494:pharmacology; D014510:Urease / Q000037:antagonists & inhibitors*; D014545:Urinary Calculi / Q000188:drug therapy* / Q000209:etiology
D006877:Hydroxamic Acids; D007477:Ions; D013424:Sulfanilamides; D007612:Kanamycin; D014510:Urease; D006918:Hydroxyurea